Stanford University has been awarded US Patent 7,393,941, “MxA as an antiviral drug and as a target for identification of antiviral drugs for DNA virus infections.”
The inventors listed on the patent are Chia-Chi Ku and Ann Arvin.
As stated in the abstract, the patent describes methods and compositions for use in a screening assay to identify agents having antiviral activity against a DNA virus by assessing the effect of a candidate agent on alternative splicing of MxA, or by assessing the effect of a candidate agent on production of a variant form of MxA protein. The patent also describes methods for enhancing resistance of cells to infection by a DNA virus by providing for elevated MxA and/or by providing for reduced production of variant MxA protein.
Johns Hopkins University has been awarded US Patent 7,393,932, “Endothelial cell expression patterns.”
The inventors listed on the patent are Eleanor Carson-Walter, Brad St. Croix, Kenneth Kinzler, and Bert Vogelstein.
The patent describes new techniques for isolating endothelial cells and evaluating gene expression patterns that were developed to gain a better understanding of tumor angiogenesis, according to its abstract. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. As mentioned in the abstract, these results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.